Relay Therapeutics, Inc. (RLAY)

Market Cap	696.31M
Revenue (ttm)	10.01M
Net Income (ttm)	-345.20M
Shares Out	167.38M
EPS (ttm)	-2.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,527,190
Open	4.200
Previous Close	4.260
Day's Range	4.150 - 4.315
52-Week Range	4.110 - 12.140
Beta	1.59
Analysts	Strong Buy
Price Target	20.11 (+383.41%)
Earnings Date	Nov 6, 2024

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Kα inhibit...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 16, 2020
• Employees: 323
• Stock Exchange: NASDAQ
• Ticker Symbol: RLAY
• Website: https://www.relaytx.com

Financial Performance

In 2023, Relay Therapeutics's revenue was $25.55 million, an increase of 1749.82% compared to the previous year's $1.38 million. Losses were -$341.97 million, 17.7% more than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price forecast is $20.11, which is an increase of 383.41% from the latest price.

Price Target

$20.11

(383.41% upside)

Analyst Consensus: Strong Buy